TRVI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Trevi Therapeutics Inc (TRVI) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the technical indicators are bullish and analysts have raised the price target, the company's financial performance is weak, with declining net income and EPS. Additionally, there are no significant positive catalysts or recent news to support a strong upward momentum. The options data and trading sentiment also do not indicate strong activity or interest in the stock. Given the user's impatience and unwillingness to wait for optimal entry points, this stock does not present a compelling long-term investment opportunity at this time.
The technical indicators for TRVI are bullish. The MACD histogram is positive and expanding, the RSI is neutral at 72.087, and the moving averages are aligned in a bullish pattern (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level of 11.525, with the next resistance at 11.978. However, the RSI suggests no clear overbought or oversold conditions.
Analyst Stifel raised the price target from $15 to $18 and maintained a Buy rating. The technical indicators are bullish, and the stock has a high probability of modest short-term gains (0.52% in the next day, 2.25% in the next week, and 8.05% in the next month).
There is no recent news or significant trading activity from insiders, hedge funds, or Congress to support a strong upward momentum. The options data shows low trading activity, with a Put-Call Ratio of 0.35 and no put volume.
In Q3 2025, the company reported no revenue growth (0.00% YoY), a net income drop to -$11.8M (-10.87% YoY), and a decline in EPS to -0.08 (-38.46% YoY). Gross margin remained at 0. The financials indicate poor performance and lack of profitability.
Stifel raised the price target from $15 to $18 and maintained a Buy rating, reflecting optimism for the company's long-term potential. However, no other analysts' ratings or updates were provided.
